A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours
作者： Shodeinde A. Coker , Uday B. Dandamudi , Andrew P. Beelen , Nancy A. Crosby , Jan L. Fisher
DOI: 10.1179/1973947813Y.0000000102
关键词: Maximum tolerated dose 、 In patient 、 Dose escalation 、 Alpha (ethology) 、 Internal medicine 、 Peg interferon 、 Pharmacology 、 Temozolomide 、 Refractory 、 Medicine 、 Pharmacokinetics 、 Oncology
摘要: AbstractBackground: Temozolomide (TMZ) is an oral alkylating agent used in the treatment of central nervous system neoplasms and metastatic melanoma. Preclinical clinical data suggested that combining TMZ with interferon alpha-2b (IFN-alpha-2b) may result increased anti-tumour efficacy.Methods: This was a phase I, dose-escalation study to define maximum tolerated dose (MTD) dose-limiting toxicities (DLT) cyclical (days 1–7 15–21) combination pegylated IFN-alpha-2b (PEG-IFN-alpha-2b) patients advanced solid tumours.Results: We treated 19 (10 female nine male), median age 58 years (range: 41–79 years). Ten at 100 mg/m2 on days 15–21 plus PEG-IFN-alpha-2b 1·5 mcg/kg/week 28-day cycles which MTD combination. The pharmacokinetic parameters were not altered by TMZ, MTD.Conclusion: 1-7 15-21 when combined weekly subc...
sci-hub.se 参考文章(21)
Stefan Zeuzem, Christoph Welsch, Eva Herrmann, Pharmacokinetics of peginterferons. Seminars in Liver Disease. ,vol. 23, pp. 23- 28 ,(2003) , 10.1055/S-2003-41631
Kazuya Motomura, Atsushi Natsume, Yugo Kishida, Hiroyuki Higashi, Yutaka Kondo, Yoko Nakasu, Tatsuya Abe, Hiroki Namba, Kenji Wakai, Toshihiko Wakabayashi, Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer. ,vol. 117, pp. 1721- 1730 ,(2011) , 10.1002/CNCR.25637
Sanjiv S. Agarwala, John M. Kirkwood, Temozolomide in combination with interferon α‐2b in patients with metastatic melanoma Cancer. ,vol. 97, pp. 121- 127 ,(2003) , 10.1002/CNCR.11041
Christian Fizames, François Lavelle, John A. Slack, David Chubb, John A. Hickman, Robert Stone, Simon P. Langdon, Colin Goddard, Ghousia Baig, Neil W. Gibson, Edward Lunt, Christopher Newton, Malcolm F. G. Stevens, Lisa Vickers, Antitumor Activity and Pharmacokinetics in Mice of 8-Carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a Novel Drug with Potential as an Alternative to Dacarbazine Cancer Research. ,vol. 47, pp. 5846- 5852 ,(1987)
Wen-Jen Hwu, Katherine S. Panageas, Jennifer H. Menell, Lynne A. Lamb, Suzan Aird, Susan E. Krown, Linda J. Williams, Paul B. Chapman, Philip O. Livingston, Jedd D. Wolchok, Alan N. Houghton, Phase II study of temozolomide plus pegylated interferon-α-2b for metastatic melanoma Cancer. ,vol. 106, pp. 2445- 2451 ,(2006) , 10.1002/CNCR.21909
Emlyn Tobillo, Melton Affrime, Thomas C. Marbury, Amy L. Pittenger, Paul Glue, Vijay Batra, Suzanne K. Swan, Marshall Sack, Sheila Jacobs, Samir K. Gupta, Single‐Dose Pharmacokinetics and Safety of Pegylated Interferon‐α2b in Patients with Chronic Renal Dysfunction The Journal of Clinical Pharmacology. ,vol. 42, pp. 1109- 1115 ,(2002) , 10.1177/009127002237996
J. U. Gutterman, Cytokine therapeutics: lessons from interferon alpha. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 91, pp. 1198- 1205 ,(1994) , 10.1073/PNAS.91.4.1198
T. Petrella, S. Verma, K. Spithoff, I. Quirt, D. McCready, Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. Clinical Oncology. ,vol. 24, pp. 413- 423 ,(2012) , 10.1016/J.CLON.2011.12.002
Toshihiko Wakabayashi, Takamasa Kayama, Ryo Nishikawa, Hiroshi Takahashi, Naoya Hashimoto, Jun Takahashi, Tomokazu Aoki, Kazuhiko Sugiyama, Masatoshi Ogura, Atsushi Natsume, Jun Yoshida, A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report. Journal of Neuro-oncology. ,vol. 104, pp. 573- 577 ,(2011) , 10.1007/S11060-011-0529-1
M D Groves, V K Puduvalli, M R Gilbert, V A Levin, C A Conrad, V H Liu, K Hunter, C Meyers, K R Hess, W K Alfred Yung, Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme British Journal of Cancer. ,vol. 101, pp. 615- 620 ,(2009) , 10.1038/SJ.BJC.6605189